Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

Author： Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.11, 2012-08, pp. : 1271-1284

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

By O'Hare Thomas   Eide Christopher A   Deininger Michael W  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 865-878

Informa Healthcare

Access to resources Recommend Favorite

BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile

By  

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2943-2959

Bentham Science Publishers

Access to resources Recommend Favorite

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

By Doggrell Sheila A   Christensen Anne-Marie  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 157-163

Informa Healthcare

Access to resources Recommend Favorite

New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 371-379

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia - is it all BCR-ABL?

By  

Current Cancer Drug Targets, Vol. 11, Iss. 1, 2011-01 ,pp. : 3-19

Bentham Science Publishers

Access to resources Recommend Favorite